-
公开(公告)号：US10905699B2
公开(公告)日：2021-02-02
申请号：US15742710
申请日：2016-06-28
申请人： Dr. Falk Pharma GmbH
IPC分类号： A01N37/00 , A61K31/215 , A01N37/12 , A01N37/44 , A61K31/24 , A01N25/00 , A61K31/58 , A61K9/02 , A61K31/606 , A61P29/00
摘要： Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.
-
2.发明授权公开(公告)号：US11382860B2
公开(公告)日：2022-07-12
申请号：US16875573
申请日：2020-05-15
申请人： Dr. Falk Pharma GmbH
发明人： Roland Greinwald , Ralph Mueller , Markus Proels , Rudolf Wilhelm
摘要： Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
-
公开(公告)号：US11173121B2
公开(公告)日：2021-11-16
申请号：US17263710
申请日：2019-08-22
申请人： Dr. Falk Pharma GmbH
摘要： An optimized pharmaceutical formulation for the treatment of inflammatory diseases of the colon is disclosed, wherein the pharmaceutical formulation is a capsule containing pellets, which capsule is suitable for oral administration and delivers the active substance in a targeted manner to the site of action, namely the colon. This is achieved by a complex and multiple coating of pellets, which permit a modified release of active substance. The release of the active substance is at its maximum only in the colon, with at the same time low blood plasma levels. The results of the pharmaceutical tests concerning in vitro release are corroborated by the results in pharmaco-kinetic and clinical studies and the clinical efficacy demonstrated by these. The formulation according to the invention has a very good medicinal safety.
-
4.发明授权公开(公告)号：US10369100B2
公开(公告)日：2019-08-06
申请号：US15833428
申请日：2017-12-06
申请人： Dr. Falk Pharma GmbH
发明人： Roland Greinwald , Ralph Mueller , Markus Proels , Rudolf Wilhelm
摘要： Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
-
5.发明申请公开(公告)号：US20180185277A1
公开(公告)日：2018-07-05
申请号：US15833428
申请日：2017-12-06
申请人： Dr. Falk Pharma GmbH
发明人： Roland Greinwald , Ralph Mueller , Markus Proels , Rudolf Wilhelm
CPC分类号： A61K9/0056 , A61K9/0007 , A61K9/2013 , A61K31/58
摘要： Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
-
公开(公告)号：US20230165844A1
公开(公告)日：2023-06-01
申请号：US17996770
申请日：2021-04-24
申请人： Dr. Falk Pharma GmbH
IPC分类号： A61K31/4439 , A61K9/48 , A61K9/20
CPC分类号： A61K31/4439 , A61K9/4866 , A61K9/2054 , A61K9/4825 , A61K9/4858
摘要： The present invention relates to a systemic formulation, in particular an oral formulation, for the prophylaxis and/or treatment of coeliac disease, i.e. for use in the prophylaxis and/or treatment of coeliac disease.
-
公开(公告)号：US11135159B2
公开(公告)日：2021-10-05
申请号：US15770569
申请日：2016-10-21
申请人： Dr. Falk Pharma GmbH
发明人： Rudolph Wilhelm , Markus Pröls , Roland Greinwald , Tanju Nacak
IPC分类号： A61K9/20 , A61K9/28 , A61P1/00 , A61K9/00 , A61K31/606
摘要： The present invention relates to an oral enteric high-dose tablet comprising mesalazine as the active substance as well as its use.
-
8.发明授权公开(公告)号：US10695291B2
公开(公告)日：2020-06-30
申请号：US16442756
申请日：2019-06-17
申请人： Dr. Falk Pharma GmbH
发明人： Roland Greinwald , Ralph Mueller , Markus Proels , Rudolf Wilhelm
摘要： Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.
-
公开(公告)号：US11850252B2
公开(公告)日：2023-12-26
申请号：US16652044
申请日：2018-09-28
申请人： Dr. Falk Pharma GmbH
发明人： Markus Pröls , Roland Greinwald , Michael Trauner , Peter Fickert
IPC分类号： A61K31/575 , A61P1/16 , A61K45/06
CPC分类号： A61K31/575 , A61P1/16 , A61K45/06
摘要： The present invention relates to the use of Nor-UDCA in the treatment of hepatic steatosis in patients having a hepatic fat fraction of greater than 10%.
-
公开(公告)号：US11738032B2
公开(公告)日：2023-08-29
申请号：US17094233
申请日：2020-11-10
申请人： Dr. Falk Pharma GmbH
IPC分类号： A01N37/00 , A61K31/215 , A01N37/12 , A01N37/44 , A61K31/24 , A01N25/00 , A61K31/58 , A61K9/02 , A61K31/606 , A61P29/00
CPC分类号： A61K31/58 , A61K9/02 , A61K31/606 , A61P29/00 , A61K31/58 , A61K2300/00 , A61K31/606 , A61K2300/00
摘要： Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.014 秒)
